MarketPulse
E

$EWTX

3 articles found
2 positive
0 negative
1 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Immutrin Bolsters Leadership With Cardiovascular Expert as CMO, Launches US Operations

Biotech firm Immutrin appoints Dr. Robert Blaustein as Chief Medical Officer and establishes US subsidiary to advance amyloidosis antibody therapy toward clinical trials.
MRKEWTXclinical developmentcardiovascular
The Motley FoolThe Motley Fool··Eric Volkman

JPMorgan Lifts Edgewise Therapeutics on Pipeline Optimism, Stock Surges

JPMorgan raises Edgewise Therapeutics price target to $45, citing positive long-term clinical data for EDG-7500 and sevasemten. Stock rises 2.18%.
AMJBJPMJPMpCJPMpDJPMpJ+5clinical databiotech
BenzingaBenzinga··Gav Blaxberg

Edgewise Therapeutics' $3.1B Bet on Two Blockbuster Drug Candidates

Edgewise Therapeutics pursues two major drug candidates addressing unmet cardiac and muscular disease needs, with pivotal data expected through 2026.
BMYCELGrALNYEWTXFDA approvalbiotech